

## ARIC Manuscript Proposal #2105

PC Reviewed: 6/11/13  
SC Reviewed: \_\_\_\_\_

Status: A  
Status: \_\_\_\_\_

Priority: 2  
Priority: \_\_\_\_\_

**1.a. Full Title:** Risk factors for incident atrial fibrillation in patients with normal left atrial size:  
The Atherosclerosis Risk in Communities Study

**b. Abbreviated Title (Length 26 characters):** Normal left atrial size and AF

**2. Writing Group members:** Waqas Qureshi, MD  
Elsayed Z. Soliman, MD, MSc, MS  
Scott Solomon, MD  
Dan Arking, PhD  
Amil Shah, MD  
Deepak Gupta, MD  
Alvaro Alonso, MD, PhD  
Lynne Wagenknecht, PhD  
David Herrington, MD, MHS

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal.

**First author:** Waqas Qureshi, MD  
Address: Wake Forest University School of Medicine  
Medical Center Blvd  
Winston-Salem, N.C. 27157  
Phone: 516 – 512 – 2605  
E-mail: waqastariq@gmail.com

**ARIC author** to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Elsayed Z. Soliman, MD, MSc, MS  
Address: Medical Center Blvd  
Winston-Salem, NC 27157-1063  
Phone: 336-716-8632  
E-mail: esoliman@wakehealth.edu

**3. Timeline:** Analysis to begin after Publication Committee approval.  
Manuscript anticipated for initial P&P review in Fall 2013

#### **4. Rationale:**

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia that currently affects 2.3 million individuals in the United States. <sup>1</sup> This prevalence is projected to increase to 16

million by 2050.<sup>2,3</sup> The total health expenditures incurred by patients with atrial fibrillation are almost 5 times that of patients without AF and range from \$6 – \$26 billion.<sup>4</sup> These patients suffer from considerable morbidity and mortality.<sup>5</sup>

In preparation for this ‘epidemic’ of AF, The National Heart, Lung, and Blood Institute convened an expert panel that has stressed the need for further epidemiological studies to further elucidate the pathophysiology of AF.<sup>6</sup> Based on these recommendations, the Framingham Study investigators developed a risk score derived for predicting incidence of AF.<sup>7</sup> Increased left atrial (LA) size, or factors that contribute to an increase in LA size, are the most frequently cited risk factors for AF.<sup>8-10</sup> However, a sizable minority of patients with new onset atrial fibrillation have normal atrial sizes.<sup>11</sup> A recent study in women showed that the traditional risk factors of AF might differ in patients with large atrium and normal atrium.<sup>12</sup> However, there are few data regarding the risk factors for developing atrial fibrillation in patients with normal atrial size. Clarifying the etiologic factors that contribute to AF in the setting of normal LA size could emphasize pathogenic mechanisms or suggest novel targets for therapeutic intervention or prevention designed to reduce the clinical and financial burden of AF in our rapidly aging population.<sup>13</sup>

Accordingly, the aims of this study are to investigate traditional risk factors in the patients with AF and to compare them between patients with and without a dilated LA.

#### **5. Specific Aims:**

The goal is to identify factors that may be uniquely associated with AF in participants with normal left atrial size. Therefore, among ARIC participants in exam 5, we will:

- 1) Examine the cross-sectional association between traditional risk factors and prevalent AF, stratified according to the presence or absence of a dilated left atrium.

#### **6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).**

##### **Study population:**

Participants with data on left atrial size by echocardiography and atrial fibrillation by electrocardiogram (ECG) in ARIC exam 5

##### **Key variables:**

- **Atrial fibrillation:** Cases of atrial fibrillation will be defined as ECG evidence of AF during exam 5, or previously documented AF during past ARIC visits (i.e. AF cases detected from ECG data in previous ARIC visits, and hospital discharge ICD codes and death certificates)
- LA size as measured by echocardiography.
- Demographics, traditional CVD/AF risk factors (hypertension, diabetes, dyslipidemia, smoking status, family history of coronary artery disease, obesity BMI >30), prevalent CVD, chronic kidney disease, relevant medications, alcohol use, and pulmonary disease.

## **Analysis Plan:**

Participants will be stratified based on left atrial size (normal and dilated/enlarged). For the purpose of stratification we will use clinically accepted definitions of LA enlargement (>40mm in women, and >45mm in men) as well as empirically derived cut-points based on the distribution of LA dimensions in the ARIC cohort ( $\geq$  vs.  $<$  75<sup>th</sup> and 90<sup>th</sup> sex-specific %tiles). In each stratum, multivariable logistic regression will be performed to determine the association of each of the individual candidate risk factors after adjustment for age, race and sex. In a second step factors that are individually associated with AF will be selected using a stepwise procedure for inclusion in a final model. If there are variables whose association with AF appears to be substantially different according to LA size, formal interaction analyses will be performed. Sensitivity analyses will also be performed to determine the impact of adjustment for AF duration prior to stratification.

### **7.a. Will the data be used for non-CVD analysis in this manuscript?**

No

### **8.a. Will the DNA data be used in this manuscript?**

Yes

### **9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status.**

Yes

### **10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?**

No previous ARIC manuscript proposals looked specifically at AF risk factors in the setting of normal LA size. However, ARIC authors involved in AF-related proposals are included as coauthors (Alvaro Alonso and Elsayed Soliman).

### **11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?**

Yes. The PI and investigators from the AF ancillary study are included as coauthors (Alvaro Alonso and Elsayed Soliman)

### **References:**

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA : the journal of the American Medical Association* 2001;285:2370-5.
2. Gersh BJ, Tsang TS, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. *Transactions of the American Clinical and Climatological Association* 2004;115:149-59; discussion59-60.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006;114:119-25.

4. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circulation Cardiovascular quality and outcomes* 2011;4:313-20.
5. Bouzas-Mosquera A, Brouillon FJ, Alvarez-Garcia N, et al. Left atrial size and risk for all-cause mortality and ischemic stroke. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2011;183:E657-64.
6. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation* 2009;119:606-18.
7. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. *Lancet* 2009;373:739-45.
8. Zatushni J. Atrial fibrillation and left atrial size. *American heart journal* 1988;115:1339-40.
9. Garber EB, Morgan MG, Glasser SP. Left atrial size in patients with atrial fibrillation: an echocardiographic study. *The American journal of the medical sciences* 1976;272:57-64.
10. Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. *Circulation* 1976;53:273-9.
11. Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. *Clinical cardiology* 2012;35:359-64.
12. Conen D, Glynn RJ, Sandhu RK, Tedrow UB, Albert CM. Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. *International journal of cardiology* 2013.
13. Barrett TW, Couch SA, Jenkins CA, Storrow AB. Prevalence of validated risk factors for developing atrial fibrillation--can we identify high-risk ED patients? *The American journal of emergency medicine* 2012;30:1581-7.